DIOVAN

Compare DIOVAN  to:
Compare
Compare

Generic Name for DIOVAN

Valsartan 40mg+, 80mg, 160mg, 320mg; +scored; tabs.

Legal Classification:

Rx

Pharmacological Class for DIOVAN

Angiotensin II receptor blocker.

Manufacturer of DIOVAN

Novartis Pharmaceuticals Corp

Indications for DIOVAN

Hypertension.

Adult dose for DIOVAN

Monotherapy and not volume-depleted: initially 80mg or 160mg once daily; max 320mg once daily. Or, add a diuretic (more effective than increasing dose above 80mg).

Children's dosing for DIOVAN

<6yrs or CrCl<30mL/min: not recommended. 6–16yrs: Initially 1.3mg/kg once daily (up to 40mg total); max 2.7mg/kg (up to 160mg) once daily. If unable to swallow tabs, or calculated dose (mg/kg) does not correspond to available tablet strengths, use suspension (see literature for susp preparation).

Contraindications for DIOVAN

Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for DIOVAN

Correct hypovolemia before beginning therapy (may need to reduce diuretic) or monitor closely for hypotension. Hepatic or severe renal impairment. Renal artery stenosis. Severe CHF (if renal function depends on renin-angiotensin-aldosterone system). Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for DIOVAN

Concomitant K+ supplements, K+ sparing diuretics, K+ containing salt substitutes may lead to hyperkalemia and, in heart failure patients, increased serum creatinine. Concomitant ACE inhibitor and β-blocker (see literature regarding heart failure patients).

Adverse Reactions for DIOVAN

Viral infection, fatigue, abdominal pain, neutropenia, rhabdomyolysis (rare).

How is DIOVAN supplied?

Tabs 40mg—30
Tabs 80mg, 160mg, 320mg—90

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.